Evaluation of the Efficacy of E2R Hypnotherapy in the Management of Chronic Insomnia in Primary Care (HypERR)
HypERR
2 other identifiers
interventional
136
1 country
35
Brief Summary
In France, the treatment of chronic insomnia relies mainly on hypnotic drugs in routine care, despite the high level of iatrogenicity. Cognitive-behavioral therapy (CBT) is recommended by the HAS as a non-pharmaceutical first-line therapy for chronic insomnia. Despite evidence of their efficacy in chronic insomnia, these therapies remain underdeveloped in France (few practitioners, time-consuming for the patient). Hypnotherapy is another non-drug intervention suitable for routine outpatient care. Among the hypnosis methods practiced in France, E2R (Emotion, Regression, Repair) is a hypnotherapy method used in general practice, particularly for chronic insomnia. To date, no clinical trials have been carried out to demonstrate its effectiveness in this pathology. The HypERR study is a multicenter, randomized, open-label study designed to evaluate the efficacy of a hypotherapy method called E2R in the management of chronic insomnia, by comparing it with standard care (without hypnosis).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Oct 2025
35 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 20, 2025
CompletedFirst Posted
Study publicly available on registry
March 27, 2025
CompletedStudy Start
First participant enrolled
October 14, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 14, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
April 14, 2027
April 2, 2026
March 1, 2026
1.5 years
March 20, 2025
March 27, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Severity of Insomnia assessed by the Insomnia Severity Index (ISI)
Insomnia Severity Index (ISI). The minimum score is 0 meaning No Insomnia, the maximum is 28 meaning Severe clinical insomnia
6 months
Secondary Outcomes (13)
Severity of Insomnia assessed by the Insomnia Severity Index (ISI)
3 months
Number of responders assessed by the Insomnia Severity index (ISI)
3 months
Number of responders assessed by the Insomnia Severity index (ISI)
6 months
Number of partial responders assessed by the Insomnia Severity index (ISI)
3 months
Number of partial responders assessed by the Insomnia Severity index (ISI)
6 months
- +8 more secondary outcomes
Study Arms (2)
Standard care
ACTIVE COMPARATORPatients will receive the usual care offered by their GP, the investigator in the study (except hypnosis).
E2R hypnosis
EXPERIMENTAL4 x 30-minute hypnotherapy sessions over 6 weeks by the hypnotherapist using the E2R method (with self-hypnosis)
Interventions
Randomization stratification on insomnia severity. In the "Standard care" group, the investigating physician will not change his or her current practice as part of the study. Treatment will be the same as usual, whether drug-based or not (psychotherapy, etc.), with the exception of hypnosis. The patients will be reviewed at 3 months and 6 months (+/- 1 week) after randomization (D0). The following study information and questionnaires will be completed according to patients' responses: ISI and PSQI self-questionnaires, Record of psychotropic medications, Record of any non-drug therapies implemented, Events that could modify sleep, Serious adverse events (EvIG) and non-serious adverse events (EvING) of a neuropsychiatric nature that occurred or worsened during the study.
Randomization stratification on insomnia severity. For the patients randomized to the Hypnosis E2R arm, patients summoned within 15 days to 3 weeks of inclusion for their first hypnotherapy session with the hypnotherapist. All patients will receive 4 hypnotherapy sessions over 6 weeks using the E2R method. The patients will be reviewed at 3 months and 6 months (+/- 1 week) after randomization (D0). The following study information and questionnaires will be completed according to patients' responses: ISI and PSQI self-questionnaires, Record of psychotropic medications, Record of any non-drug therapies implemented, Practice of self-hypnosis requested of the patient (patient diary), Events that could modify sleep, Serious adverse events (EvIG) and non-serious adverse events (EvING) of a neuropsychiatric nature that occurred or worsened during the study.
Eligibility Criteria
You may qualify if:
- Patient aged 18 or over,
- Patient suffering from chronic insomnia according to the DSM-5 definition, whether or not treated with psychotropic drugs:
- \* At least one of the following sleep disorders: difficulty in falling asleep, difficulty in maintaining sleep, waking up too early and inability to go back to sleep, and \* At least 3 nights a week for at least 3 months, and \* In an adequate night-time sleep context, and \* With at least one significant impact on, or impairment of, social, occupational or behavioral functioning, and \* Insomnia not attributable to the physiological effects of a substance, and \* Insomnia not explicable by a medical condition or mental disorder.
- Patient willing to undergo hypnotherapy for 4 sessions of 30 min over 6 weeks,
- Patient whose treating physician is the investigator,
- Patient able to give free, informed, written consent,
- Patient affiliated to the French social security system.
You may not qualify if:
- Patient participating in another study involving the treatment of insomnia or another pathology having an impact on sleep disorders,
- Patient unable to complete a self-administered questionnaire,
- Patients with poor or no understanding of the French language,
- Patients unable to attend hypnotherapy consultations,
- Deaf or hard-of-hearing patients without hearing aids,
- Patient under legal protection (safeguard of justice, curatorship, guardianship) or deprived of liberty,
- Women declaring themselves pregnant or breastfeeding.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Rennes University Hospitallead
- University of Rennescollaborator
Study Sites (35)
Cabinet médical
Bain-de-Bretagne, France
Cabinet médical de Plaisance
Bouaye, France
Cabinet médical de Plaisance
Bouaye, France
Cabinet médical de Breteil
Breteil, France
Cabinet médical
Cesson-Sévigné, France
Cabinet médical du Linon
Combourg, France
Cabinet médical Sycamore
Contres, France
Cabinet médical de Corps Nuds
Corps-Nuds, France
Cabinet médical des Embruns
Crac'h, France
Pôle Santé Physiomast
Dol-de-Bretagne, France
MSP de l'Esplanade
Guer, France
Maison médicale
Iffendic, France
Cabinet Médical Chantepie
Joué Les Tours, France
Cabinet Médical de Jugon-Les-Lacs -Saint-Igneuc
Jugon-les-Lacs, France
Maison médicale des Longrais
La Chapelle-des-Fougeretz, France
Cabinet médical
La Chapelle-Saint-Ursin, France
Cabinet médical du Lion d'Or
Nantes, France
Maison médicale Laennec
Pleudihen-sur-Rance, France
Maison De Santé De Ronsouze
Ploërmel, France
Cabinet médical Les Petits Ponts
Pont-Saint-Martin, France
Cabinet médical Les Petits Ponts
Pont-Saint-Martin, France
Maison de Santé de Questembert
Questembert, France
Cabinet médical Olec
Rennes, France
Cabinet médical
Rennes, France
Maison médicale pluridisciplinaire
Rouziers-de-Touraine, France
Maison médical de Maen roch
Saint-Brice-en-Coglès, France
Maison médicale
Saint-Gilles-Croix-de-Vie, France
Maison médicale
Saint-Gilles-Croix-de-Vie, France
Maison de soin du Couesnon
Saint-Ouen-des-Alleux, France
Cabinet médical
Saint-Romain-sur-Cher, France
Maison de santé
Sancerre, France
Cabinet médical de la Blanchisserie
Sully-sur-Loire, France
Maison de santé
Talensac, France
Cabinet des médecins généralistes de TIGY
Tigy, France
Cabinet médical
Vildé-Guingalan, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Eric MENER, Ph D
University of Rennes (Department of general practice)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 20, 2025
First Posted
March 27, 2025
Study Start
October 14, 2025
Primary Completion (Estimated)
April 14, 2027
Study Completion (Estimated)
April 14, 2027
Last Updated
April 2, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will share
After informing patients, In accordance : data protection provisions (GDPR and French Data Protection Act) : Intention to share individual data All individual data collected during the study, after pseudonymization and minimization Protocol, amendments, observation log, information sheet and research consent form, statistical analysis plan, statistical analysis code, statistical report, study report without personal data, list of tables, variables and their definitions Data availability : Immediately after publication of the main analysis results and until the database is deleted Data recipients: Project leaders whose reuse has been approved by the sponsor (owner of the study data) and by the study steering committee Types of analyses: Analyses enabling the objectives defined in the sharing agreement to be achieved, which will be drawn up at the time of sharing Access via data request form sent to the promoter and data sharing agreement signed before any data is made available